会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 76. 发明授权
    • Pyrazoline compounds compositions and use
    • 吡唑啉化合物组合物和用途
    • US4824859A
    • 1989-04-25
    • US606867
    • 1984-05-03
    • Sidney C. BurfordDavid N. Hardern
    • Sidney C. BurfordDavid N. Hardern
    • C07D231/06C07D401/04C07D401/12A61K31/415
    • C07D231/06C07D401/04C07D401/12
    • There are described compounds of formula I, ##STR1## in which Ar.sub.1 and Ar.sub.2, which may be the same or different, each independently represent phenyl or pyridinyl, the phenyl or the pyridinyl each optionally being substituted by one or more of halogen; hydroxy; --COOR.sub.12 ; trihalomethyl; alkoxy C1 to 6; alkyl C1 to 6; --NR.sub.1 R.sub.2 ; alkoxy C1 to 6 substituted by --NR.sub.1 R.sub.2 or by phenyl; or alkyl C1 to 6 substituted by --NR.sub.1 R.sub.2 or by --COOR.sub.12 ;R.sub.1 and R.sub.2, which may be the same or different, each independently represent hydrogen or alkyl C1 to 6,R.sub.3 represents hydrogen, alkyl C1 to 6, alkanoyl C1 to 6, benzoyl, --COOR.sub.8, or --CONHR.sub.11,R.sub.4, R.sub.5, R.sub.6 and R.sub.7, which may be the same or different each independently represent hydrogen, alkyl C1 to 6 or phenyl,R.sub.8 represents alkyl C1 to 6 or aryl,R.sub.11 represents alkyl C1 to 6 or aryl,R.sub.12 represents hydrogen or alkyl C1 to 6, and pharmaceutically acceptable derivatives thereof.There are also described compositions containing the compounds and methods for their preparation.The compounds are indicated for use as pharmaceutical, eg antiinflammatory agents.
    • 描述了式I的化合物,其中Ar 1和Ar 2可以相同或不同,各自独立地表示苯基或吡啶基,苯基或吡啶基各自任选被一个或多个卤素取代; 羟基; -COOR12; 三卤甲基 烷氧基C1至6; 烷基C1至6; -NR1R2; 被-NR 1 R 2取代的C 1-6烷氧基或苯基取代; 或被-NR 1 R 2或-COOR 12取代的C 1-6的烷基; R1和R2可以相同或不同,各自独立地表示氢或C1至6的烷基,R3表示氢,C1至6的烷基,C1至6的烷酰基,苯甲酰基,-COOR8或-CONHR11,R4,R5,R6 和R 7可以相同或不同,各自独立地表示氢,烷基C1至6或苯基,R8表示烷基C1至6或芳基,R11表示烷基C1至6或芳基,R12表示氢或C1-6烷基,和 药学上可接受的衍生物 还描述了含有这些化合物的组合物及其制备方法。 化合物被指示用作药物,例如抗炎剂。
    • 77. 发明授权
    • Pyrazoline compounds and method of whitening
    • 吡唑啉化合物和美白方法
    • US4816590A
    • 1989-03-28
    • US935911
    • 1986-11-28
    • Hans R. Meyer
    • Hans R. Meyer
    • C07D231/06C09B67/22D06L3/12D06L3/06
    • C07D231/06D06L3/1257
    • The invention relates to pyrazoline compounds of formula ##STR1## wherein R.sub.1 is hydrogen or methyl, R.sub.2 and R.sub.3 are each independently of the other methyl, ethyl or hydroxyethyl, R.sub.4 is hydrogen or chlorine, R.sub.5 and R.sub.6 are each independently of the other hydrogen or methyl, R.sub.7 is hydrogen, methyl or phenyl, n is 0 or 1, with the proviso that, if n is 0 and R.sub.4 to R.sub.7 are hydrogen, R.sub.2 is methyl and R.sub.3 is hydroxyethyl, and X.sup..crclbar. is a C.sub.1 -C.sub.3 alkanoate, C.sub.1 -C.sub.4 alkanephosphonate, C.sub.1 -C.sub.4 alkanesulfonate, phosphite, sulfamate or glycolate anion and, if R.sub.1 is methyl, X.sup..crclbar. is also a methosulfate, chloride or bromide ion, to the preparation of said compounds, to the use thereof as fluorescent whitening agents, and to novel hydrazine intermediates of formula ##STR2## wherein R.sub.2 and R.sub.3 are methyl, ethyl or hydroxyethyl, and the acetone hydrazones and salts thereof.
    • 本发明涉及式IMA的吡唑啉化合物,其中R 1是氢或甲基,R 2和R 3各自独立地是甲基,乙基或羟乙基,R 4是氢或氯,R 5和R 6各自独立地是氢或 甲基,R 7为氢,甲基或苯基,n为0或1,前提条件是如果n为0,且R4至R7为氢,则R2为甲基,R3为羟乙基,X( - )为C1-C3烷酸酯 C1-C4烷基膦酸酯,C1-C4烷基磺酸盐,亚磷酸盐,氨基磺酸盐或乙醇酸盐阴离子,如果R1是甲基,X( - )也是一种硫酸盐,氯化物或溴离子,用于制备所述化合物,作为荧光增白剂 试剂,以及式IMA图的新型肼中间体,其中R2和R3是甲基,乙基或羟乙基,以及丙酮腙及其盐。